US biopharma Apellis Pharmaceuticals announced a capped royalty purchase agreement with Swedish Orphan Biovitrum where ...

US women’s health focused drugmaker Organon (NYSE: OGN) yesterday revealed disappointing results from the Phase II ELENA ...

The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Lynozyfic ...

The chronic kidney disease (CKD) anemia market across the seven major markets (7MM) is forecast to grow at a compound annual ...

A clinical-stage biotech company based in Los Altos, California, developing treatments for kidney diseases.

US biopharma Syntis Bio, which is developing oral therapies for obesity, diabetes and rare diseases, has announced the close ...

Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese ...

US biotech Jazz Pharmaceuticals yesterday announced that the European Commission (EC) has granted conditional marketing ...

Australian neurodegenerative diseases specialist Neurizon Therapeutics has agreed an exclusive global license agreement with ...

A federal judge has blocked the US Department of Health and Human Services from moving forward with a major workforce ...

Hungarian drugmaker Gedeon Richter has announced that the European Commission has granted marketing authorization for the biosimilar denosumab products Junod and Yaxwer.

Under the terms of the deal, HanchorBio will receive an upfront payment of $10 million, with additional payments tied to ...